Last reviewed · How we verify
Hyperbaric Bupivacaine HCl 0.5% 12.5 mg
Hyperbaric Bupivacaine HCl 0.5% 12.5 mg is a Small molecule drug developed by Aswan University. It is currently FDA-approved. Also known as: Standard dose of hyperbaric bupivacaine.
Hyperbaric Bupivacaine HCl 0.5% 12.5 mg, developed by Aswan University, is a marketed anesthetic with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, though specific revenue figures are not available. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Hyperbaric Bupivacaine HCl 0.5% 12.5 mg |
|---|---|
| Also known as | Standard dose of hyperbaric bupivacaine |
| Sponsor | Aswan University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparing Doses of Intrathecal Dexmedetomidine (PHASE4)
- HEIGHT-BASED AND CONVENTIONAL SPINAL ANAESTHETIC DOSING IN GERIATRIC PATIENTS (NA)
- Intrathecal Dexamethasone and Atropine on Morphine Induced Post-operative Nausea and Vomiting on Caesarean Section (NA)
- Hemodynamics During Cesarean Delivery Under Spinal Anesthesia With Norepinephrine Versus Ephedrine (PHASE4)
- Comparison of Classic and Sequential Spinal Techniques for Preventing Hypotension During Cesarean Delivery. (PHASE3)
- ED50 of Dexmedetomidine as an Adjuvant to 0.5% Hyperbaric Bupivacaine 12.5 mg for Spinal Anesthesia in Hip and Knee Surgery: An Up-and-Down Method Approach (NA)
- Effect of a 20% Reduction in Hyperbaric Bupivacaine Dose on High Spinal Block Incidence in Cesarean Delivery: A Risk-Stratified Randomized Controlled Trial. (PHASE4)
- Comparison of Magnesium Sulphate vs Tramadol as Adjuvants in Intrathecal Bupivacaine for Postoperative Pain in TURP Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hyperbaric Bupivacaine HCl 0.5% 12.5 mg CI brief — competitive landscape report
- Hyperbaric Bupivacaine HCl 0.5% 12.5 mg updates RSS · CI watch RSS
- Aswan University portfolio CI
Frequently asked questions about Hyperbaric Bupivacaine HCl 0.5% 12.5 mg
What is Hyperbaric Bupivacaine HCl 0.5% 12.5 mg?
Who makes Hyperbaric Bupivacaine HCl 0.5% 12.5 mg?
Is Hyperbaric Bupivacaine HCl 0.5% 12.5 mg also known as anything else?
What development phase is Hyperbaric Bupivacaine HCl 0.5% 12.5 mg in?
Related
- Manufacturer: Aswan University — full pipeline
- Also known as: Standard dose of hyperbaric bupivacaine
- Compare: Hyperbaric Bupivacaine HCl 0.5% 12.5 mg vs similar drugs
- Pricing: Hyperbaric Bupivacaine HCl 0.5% 12.5 mg cost, discount & access